<DOC>
	<DOCNO>NCT00346268</DOCNO>
	<brief_summary>The primary objective study demonstrate opioid-sparing efficacy parecoxib 40 mg intravenously give load dose follow 20 mg intravenously 24 hour end surgery .</brief_summary>
	<brief_title>Morphine-Sparing Efficacy Of Parecoxib In Pain Treatment After Radical Prostatectomy</brief_title>
	<detailed_description>The study terminate due lack recruitment due compete alternative operation method 13September 2010 . The decision terminate trial base safety concern .</detailed_description>
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Parecoxib</mesh_term>
	<criteria>The patient 's ASA physical status 1 2 low risk ( i.e. , &lt; 10 % ) develop acute coronary event within next 10 year accord PROCAM risk assessment calculator . The patient schedule undergo routine radical prostatectomy perform standardized regimen general anesthesia , expect experience moderate severe postsurgical pain absence postoperative analgesia . The patient history uncontrolled chronic disease concurrent clinically significant illness medical condition diagnose chronic pain condition , , Investigator 's opinion , would contraindicate study participation confound interpretation result The patient history current presence congestive heart failure ( NYHA IIIV ) , establish ischaemic heart disease , peripheral arterial disease / cerebrovascular disease .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>